statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024...

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

Futures Flat As Post-FOMC Rally Takes A Breather

 US stock futures are flat after the S&P 500 and Nasdaq 100 both closed 1% higher on Monday, helped by growing optimism among investors...

Futures Flat As Post-FOMC Rally Takes A Breather

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of...

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30...

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR  Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They...

HC Wainwright Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)

It has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares have added about 2% in that time frame, underperforming the S&P 500.Will the recent positive trend...

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President...

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen...

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic...

U.S. FDA Approves Broad New Labels for Esperions NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

NEXLETOL (bempedoic acid) Tablet

 New Labels Expand Treatable Population to ~70 Million Patients in U.S. First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients...

U.S. FDA Approves Broad New Labels for NEXLETOL  and NEXLIZET  to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Watchers	8,319
52-Wk Low	$0.70
52-Wk High	$3.40

Volume	5.2M
52-Wk High	$3.40
52-Wk Low	$0.70

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.18	--	--	N/A
Q1'24	$0.05	$0.34	598.27%	BEAT
Q4'23	-$0.48	-$0.50	-3.80%	MISSED
Q3'23	-$0.43	-$0.37	13.56%	BEAT
Q2'23	-$0.61	-$0.46	24.76%	BEAT

ESPR Esperion Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals